Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Warrants (BFRGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: BFRGW (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 61.76% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 |
52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Warrants
Company Overview
History and Background
Bullfrog AI Holdings, Inc. is a biotechnology company focused on using artificial intelligence and machine learning to improve drug development. The warrants represent the right to purchase shares of Bullfrog AI Holdings, Inc. at a specified price and date. Bullfrog AI Holdings, Inc. went public on January 4, 2024, and trades on the Nasdaq market.
Core Business Areas
- Artificial Intelligence: Developing and applying AI/ML technologies to analyze complex data sets in drug development and precision medicine.
- Drug Development: Partnering with pharmaceutical companies to improve drug efficacy and reduce development costs through AI-driven insights.
- Biotechnology: Utilizing bioinformatics and computational biology to advance healthcare solutions.
Leadership and Structure
The leadership team includes experts in AI, biotechnology, and drug development. The organizational structure consists of departments focusing on AI research, data analysis, drug development partnerships, and business development.
Top Products and Market Share
Key Offerings
- bfLEAPu2122: bfLEAP is Bullfrog AI's proprietary AI/ML platform designed to identify actionable insights from complex biological data. It helps predict drug efficacy, identify patient subgroups that respond to therapy, and optimize clinical trials. Market share data is not publicly available due to the niche nature of the offering. Competitors include companies offering similar AI platforms for drug discovery and development, such as Schrodinger, Exscientia, and Recursion Pharmaceuticals.
Market Dynamics
Industry Overview
The biotechnology and AI-driven drug discovery industry is rapidly growing, driven by the increasing complexity of biological data and the need for more efficient drug development processes. There is a strong emphasis on personalized medicine and precision diagnostics.
Positioning
Bullfrog AI positions itself as an innovator in AI-driven drug development, focusing on improving clinical trial outcomes and personalized medicine. Their competitive advantage lies in the bfLEAPu2122 platform's unique capabilities.
Total Addressable Market (TAM)
The total addressable market for AI in drug discovery is projected to reach billions of dollars. Bullfrog AI is positioned to capture a segment of this market by providing their proprietary AI platform and expertise to pharmaceutical and biotech companies.
Upturn SWOT Analysis
Strengths
- Proprietary AI platform (bfLEAPu2122)
- Expertise in AI/ML and biotechnology
- Focus on precision medicine
- Partnerships with pharmaceutical companies
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on partnerships for revenue generation
- Relatively small market capitalization
- Relatively new company
Opportunities
- Expanding partnerships with pharmaceutical companies
- Developing new AI-driven applications for drug discovery
- Entering new markets
- Advancements in AI and machine learning
- Increase adoption of precision medicine
Threats
- Competition from larger companies with more resources
- Regulatory hurdles in drug development
- Rapid technological advancements that could render their AI platform obsolete
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- SCHR
- RXRX
- CRSP
Competitive Landscape
Bullfrog AI competes with larger companies that have established AI platforms and extensive resources. Their competitive advantage lies in the specialized application of their AI platform to precision medicine and drug development, which allows them to offer tailored solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent establishment. However, the company shows strong initial interest from pharma partners.
Future Projections: Future growth is dependent on the success of their partnerships, adoption of the bfLEAPu2122 platform, and ability to secure funding. Analyst estimates are not widely available at this stage.
Recent Initiatives: Recent initiatives include forging new partnerships with pharmaceutical companies and expanding the capabilities of the bfLEAPu2122 platform.
Summary
Bullfrog AI Holdings, Inc. Warrants represent a speculative investment tied to a biotechnology company with a promising AI platform. The company shows potential due to its focus on precision medicine and partnerships with pharmaceutical companies. However, it faces risks associated with competition, regulatory hurdles, and dependence on successful clinical trials. Investors should carefully evaluate the risks and potential rewards before investing in the warrants.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Analysis Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence. Financial data is based on preliminary estimates and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-14 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2 | Website |
Full time employees 2 | Website | ||
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.